Should testosterone be given subcutaneously rather than intramuscularly in an adult male with primary or secondary hypogonadism?

Subcutaneous vs Intramuscular Testosterone Administration

For adult males with hypogonadism, intramuscular testosterone remains the standard route based on established guidelines and FDA labeling, though subcutaneous administration is an effective and increasingly supported alternative that offers comparable efficacy with potential advantages in patient comfort and convenience.

Route Selection Algorithm

The choice between subcutaneous (SQ) and intramuscular (IM) routes should follow this decision framework:

Primary Consideration: Cost and Accessibility

• IM testosterone is significantly less expensive than transdermal formulations and should be considered first when injectable therapy is chosen 1
• The American College of Physicians specifically recommends considering IM over transdermal formulations due to substantially lower costs with similar clinical effectiveness and safety profiles 1

FDA-Approved Standard

• Testosterone cypionate and enanthate are FDA-approved for intramuscular use only 2
• The official labeling states these products "should not be given intravenously" and specifies "intramuscular injections should be given deep in the gluteal muscle" 2
• Standard IM dosing: 50-400 mg every 2-4 weeks, though more frequent smaller doses (50-150 mg every 7-14 days) maintain more stable levels 3

When to Consider Subcutaneous Administration

Despite lack of FDA approval for this route, consider SQ when:

1. Patient preference for self-administration: SQ injections are easier to self-administer and virtually painless 4
2. Desire for more stable levels: Weekly SQ dosing produces steadier testosterone concentrations with smaller peak-trough fluctuations 4, 5
3. IM injection intolerance: Patients experiencing significant discomfort with IM injections 5, 6
4. Need for frequent dosing: When symptom cycling occurs with standard IM intervals 7

Evidence Supporting Subcutaneous Use

Efficacy Data

The most robust evidence comes from a 52-week registration study showing:

• 92.7% of patients achieved target testosterone levels (300-1,100 ng/dl) with weekly SQ auto-injector 4
• Mean trough concentration of 487.2 ng/dl at week 52 4
• 100% of patients in smaller studies achieved normal range levels with weekly SQ dosing 8

Comparative Studies

A crossover study directly comparing routes demonstrated:

• Equivalent total testosterone exposure between SQ and IM (AUC 1.7 vs 1.9 nmol·days/L/mg, p>0.05) 6
• Superior tolerability with SQ: lower preinjection anxiety, less pain during injection, and reduced postinjection pain 6
• Among 22 patients switching from IM to SQ, 20 had marked preference for SQ and none preferred IM 5

Safety Profile

• Minor, transient local reactions in only 9/63 patients (14%) 5
• No study drug-related serious adverse events in the 52-week trial 4
• Effective across wide BMI range (19.0-49.9 kg/m²) 5

Practical Implementation

Intramuscular Dosing

• Weekly: 75-100 mg (preferred for stable levels) 3
• Every 2 weeks: 150-200 mg 3
• Alternative: 100 mg on days 1,11, and 21 of each month 9

Subcutaneous Dosing

• Start with 50-75 mg weekly 4, 8, 5
• Adjust to 50,75, or 100 mg based on week 6 trough levels 4
• Use 0.5 ml insulin syringe for self-administration 8

Monitoring Strategy

Timing of testosterone measurement differs by route:

• IM injections: Measure midway between injections, targeting mid-normal range (500-600 ng/dl) 10
• SQ injections: Can measure at any time due to more stable levels 6

Standard monitoring schedule (both routes):

• 3 months after initiation, then every 6-12 months 3
• Hematocrit at baseline, 3 months, then annually (stop if >54%) 3
• PSA and digital rectal exam at baseline, 3 months, then per screening guidelines 3

Critical Caveats

Guideline Discrepancy

While established guidelines from 2003-2006 only mention IM administration 9, 3, more recent evidence (2017-2019) strongly supports SQ as equally effective 4, 5, 6. The FDA label has not been updated to include SQ administration 2.

Cardiovascular Considerations

• 2017 guidance notes potential increased cardiovascular risk with testosterone injections compared to gels 10
• This may relate to supraphysiologic peaks with standard IM dosing 10
• More frequent, lower-dose injections (whether IM or SQ) may mitigate this concern 7

Common Pitfall

Do not default to every-2-week IM dosing out of habit 7. Many patients experience symptom cycling with this interval. Weekly or more frequent administration produces more stable levels and better symptom control 7.

Bottom Line Recommendation

Start with weekly IM testosterone (75-100 mg) as the evidence-based, cost-effective standard 3, 1. Switch to weekly SQ administration (50-75 mg) if the patient prefers self-administration, experiences IM injection discomfort, or demonstrates symptom cycling with IM dosing 4, 5, 6. Both routes achieve equivalent testosterone exposure and clinical outcomes when dosed appropriately, but SQ offers superior patient acceptability in head-to-head comparisons 5, 6.